Status:
COMPLETED
Efficacy and Safety of Fluvastatin in Different Doses in Adults With Mixed Dyslipidemia or Primary Hypercholesterolemia
Lead Sponsor:
Novartis
Conditions:
Mixed Dyslipidemia
Hypercholesterolemia
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
The purpose of the study is to evaluate the safety and tolerability of fluvastatin 80 mg in a Chinese population. This study is not recruiting patients in the US.
Eligibility Criteria
Inclusion
- Mixed dyslipidemia
- Primary hypercholesterolemia
Exclusion
- Pregnant or lactating women
- Age \> 18 years
- Other protocol-defined inclusion and exclusion criteria may apply.
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2006
Estimated Enrollment :
325 Patients enrolled
Trial Details
Trial ID
NCT00136799
Start Date
June 1 2005
End Date
April 1 2006
Last Update
February 23 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis
Shanghai, China